Tyme Technologies, Inc.Company Review & Valuation

TYME
Nasdaq
Latest Price
0.87USD
Market Capitalization
106.64mUSD

About Tyme Technologies, Inc.

Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The compaShow moreny was founded in 2011 and is headquartered in New York, New York.Show less

Industry
Biotechnology
HQ Location
New York, New York

Stock Price

Price data not available for Tyme Technologies, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

MannKind Corporation
BioCryst Pharmaceuticals
Protalix BioTherapeutics
Regenxbio

back to top